Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
Xuezhu XuRui LiuAili HeFangxia Wang
Abstract
Our results showed that the combination of VEN + HMA appeared to be a highly effective and well-tolerated salvage therapy option for young patients with R/R AML, enabling more young patients to proceed to potentially curative allo-HSCT. However, additional, well-designed studies with larger numbers of patients are required to confirm the advantages of VEN + HMA in this population.
Metrics
Citation History
Topics
Related Documents
Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia
Hongxia WangJunjun BaiZhixin PeiBei ZhangJunjie WangXingli LianQinglin Song
Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML.
Mehmet Ali UçarGülsüm ÖzetMahmut Bakır KoyuncuMehmet SönmezOsman AkıdanMeltem AylıMurat YıldırımMustafa PehlıvanDervis Murad AkkurtHanifi ŞahinBirol GüvençVahap OkanEyüp Naci TiftikAydan AkdenizHüseyin Derya DinçyürekA K GunesSimten Dağdaşİbrahim Halil AçarHavva UcarAnıl Tombak
Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
Nerea Báez‐GutiérrezHéctor Rodríguez RamalloMaría Antonia Pérez-MorenoEduardo-Rodriguez ArboliLaila Abdel‐Kader Martín
Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents.
Carl ZainaldinSankalp AroraSri BathiniVishruti PandyaSejong BaeUdita GuptaSarah WorthKimo BachiashviliRavi BhatiaKelly GodbyOmer JamySravanti RangarajuBarry DiamondJosh OliverDonna SalzmanAntonio Di StasiPankit Vachhani